GSC
EFTR

Ground Swell Capital’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Ground Swell Capital’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-470
Closed -$4.23K – 98
2023
Q1 		$4.23K Buy
+470
New +$5.7K 0.01% 54

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOA
Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return

Ground Swell Capital's EFTR Position: Q2 2023 in Review

Ground Swell Capital sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q2 2023, closing a stake of 470 shares — an estimated $4.23K sold.

Ground Swell Capital first reported a position in EFTR in Q1 2023 and held it in 1 quarter. The position peaked at $4.23K in Q1 2023. 33 funds tracked by Wall St. Rank hold EFTR as of Q2 2023.

  • Ground Swell Capital reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ground Swell Capital sold 470 eFFECTOR Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.23K.
  • Ground Swell Capital first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Ground Swell Capital's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $4.23K in Q1 2023.
  • 33 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Ground Swell Capital's 13F filing for Q2 2023, filed 10 Aug 2023.